Related Experiment Videos
High prevalence of circulating antibodies to MuLV p30 antigen in human sera. An autoimmune response?
A Kovarík1, K Hlubinová, J Prachar
1Cancer Research Institute, Slovak Academy of Sciences, Bratislava, CSFR.
Abstract:
To study the possible involvement of a murine leukemia virus (MuLV) related agent in human cancer, an extensive immunoblotting analysis of human sera (cancer, autoimmune as well as control normal ones) for the presence of antibodies to MuLV structural proteins was performed. Out of 350 sera, 89 reacted with gag precursor Pr65, 72 reacted with major viral core protein p30 and five with the matrix protein p15. Antibody reactivity to the env-encoded glycoprotein gp70 was detected in 7 cases out of 16 sera tested. There were no significant differences between pathological and normal sera concerning the patterns and the frequency of the reactivity. Sera from patients with various malignancies (mainly with breast cancer) generally displayed more intensive signals to MuLV p30 than normal sera. Epitope mapping revealed that MuLV p30-reactive antibodies recognize an antigenic determinant(s) located at the carboxyterminus of the protein.
Insights
This study investigated murine leukemia virus (MuLV) links to human cancers. Researchers found no significant differences in antibody responses between cancer patients and healthy individuals, though some cancer patients showed stronger signals to MuLV p30 protein.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Murine leukemia virus (MuLV) related agents are investigated for potential roles in human cancers.
- Understanding viral involvement in oncogenesis requires analyzing immune responses to viral proteins.
Purpose of the Study:
- To assess the presence of antibodies against MuLV structural proteins in human sera, including those from cancer patients, autoimmune disease patients, and healthy controls.
- To determine if MuLV-related agents are associated with human malignancies.
Main Methods:
- Extensive immunoblotting analysis was performed on 350 human sera samples.
- Antibody reactivity was tested against MuLV gag precursor Pr65, core protein p30, matrix protein p15, and envelope glycoprotein gp70.
Main Results:
- Antibodies to MuLV proteins (Pr65, p30, p15, gp70) were detected in a subset of human sera.
- No significant differences in antibody reactivity patterns or frequency were observed between pathological (cancer, autoimmune) and normal sera.
- Sera from patients with malignancies, particularly breast cancer, showed more intensive signals against MuLV p30 compared to normal sera.
- Epitope mapping indicated that antibodies reactive to MuLV p30 target a determinant at its carboxyterminus.
Conclusions:
- The study found no definitive link between MuLV-related agents and human cancer based on overall antibody reactivity.
- A subset of individuals, including some cancer patients, possess antibodies recognizing MuLV structural proteins.
- Further research may be needed to clarify the role of specific viral components or immune responses in human oncogenesis.